Mitochondrial delivery of bongkrekic acid using a MITO-porter prevents the induction of apoptosis in human hela cells

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 1008-1015

  Yamada, Yuma ^a   Nakamura, Kohei ^a   Furukawa, Ryo ^a   Kawamura, Eriko ^a   Moriwaki, Takuya ^b   Matsumoto, Kenji ^b   Okuda, Katsuhiro ^b   Shindo, Mitsuru ^b   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Antiapoptotic effect; Biomaterials; Bongkrekic acid; Cell culture; Liposomes; MITO Porter; Mitochondria; Mitochondrial medicine; Nanotechnology; Targeted drug delivery

Indexed keywords

BONGKREKIC ACID; CASPASE 3; CASPASE 7; LIPID; MITO PORTER; NANOCARRIER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONFOCAL LASER MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION;

EID: 84878121115     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23442     Document Type: Article

References (29)

1. Estaquier J, Vallette F, Vayssiere JL, Mignotte B. 2012. The mitochondrial pathways of apoptosis. Adv Exp Med Biol 942:157-183.
2. Tait SW, Green DR. 2010. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11(9):621-632.
3. Schapira AH. 2012. Mitochondrial diseases. Lancet 379(9828):1825-1834.
4. Scatena R. 2012. Mitochondria and drugs. Adv Exp Med Biol 942:329-346.
5. Yamada Y, Akita H, Kogure K, Kamiya H, Harashima H. 2007. Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7(1-2):63-71.
6. Bruijn JD, Frost DJ, Nugteren DH, Gaudemer A, Lijmbach GW, Cox HC, Berends W. 1973. Structure of bongkrekic acid. Tetrahedron 29(11):1541-1547.
7. Henderson PJ, Lardy HA. 1970. Bongkrekic acid. An inhibitor of adenine nucleotide translocase of mitochondria. J Biol Chem 245(6):1319-1326.
8. Klingenberg M, Grebe K, Heldt HW. 1970. On the inhibition of the adenine nucleotide translocation by bongkrekic acid. Biochem Bioph Res Commun 39(3):344-351.
9. Zamzami N, Marchetti P, Castedo M, Hirsch T, Susin SA, Masse B, Kroemer G. 1996. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. Febs Lett 384(1):53-57.
10. Zamzami N, Susin SA, Marchetti P, Hirsch T, GomezMonterrey I, Castedo M, Kroemer G. 1996. Mitochondrial control of nuclear apoptosis. J Exp Med 183(4):1533-1544.
11. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A, Hirsch F, Geuskens M, Kroemer G. 1996. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184(3):1155-1160.
12. Corey EJ, Tramontano A. 1984. Total synthesis of bongkrekic acid. J Am Chem Soc 106(2):462-463.
13. Pei YZ, Carroll AK, Anderson CM, Moos WH, Ghosh SS. 2003. Design and combinatorial synthesis of N-acyl iminodiacetic acids as bongkrekic acid analogues for the inhibition of adenine nucleotide translocase. Synthesis-Stuttgart (11):1717-1721.
14. Kanematsu M, Shindo M, Yoshida M, Shishido K. 2009. Total synthesis of bongkrekic acid via sequential Suzuki-Miyaura coupling reactions. Synthesis-Stuttgart (17):2893-2904.
15. Shindo M, Sugioka T, Umaba Y, Shishido K. 2004. Total synthesis of (+)-bongkrekic acid. Tetrahedron Lett 45(48):8863-8866.
16. Sato Y, Aso Y, Shindo M. 2009. Efficient synthesis of bongkrekic acid. Three-component convergent strategy. Tetrahedron Lett 50(28):4164-4166.
17. Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H. 2008. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778(2):423-432.
18. Yamada Y, Harashima H. 2008. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 60(13-14):1439-1462.
19. Yamada Y, Akita H, Harashima H. 2012. Multifunctional envelope-type nano device (MEND) for organelle targeting via a stepwise membrane fusion process. Methods Enzymol 509:301-326.
20. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima H. 2008. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J Biol Chem 283(34):23450-23461.
21. Khalil IA, Kogure K, Futaki S, Harashima H. 2006. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 281(6):3544-3551.
22. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, Harashima H, Sugiura Y. 2001. Stearylated arginine-rich peptides: A new class of transfection systems. Bioconjug Chem 12(6):1005-1011.
23. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. 2001. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276(8):5836-5840.
24. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, Jones AT, Sugiura Y, Futaki S. 2004. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol Ther 10(6):1011-1022.
25. Yamada Y, Kawamura E, Harashima H. 2012. Mitochondrial-targeted DNA delivery using a DF-MITO-Porter, an innovative nano carrier with cytoplasmic and mitochondrial fusogenic envelopes. J Nanopart Res 14(8):1013.
26. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S. 2002. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A 99(26):17107-17112.
27. Del Gaizo V, Payne RM. 2003. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 7(6):720-730.
28. Chen SP, Yang HL, Her GM, Lin HY, Jeng MF, Wu JL, Hong JR. 2006. Betanodavirus induces phosphatidylserine exposure and loss of mitochondrial membrane potential in secondary necrotic cells, both of which are blocked by bongkrekic acid. Virology 347(2):379-391.
29. Stubbs M. 1979. Inhibitors of the adenine-nucleotide translocase. Pharmacol Therapeut 7(2):329-350.